Amplia Therapeutics (ASX:ATX) Buyback Yield %: -37.56 (As of Jul. 03, 2026)


ASX:ATX Amplia Therapeutics Ltd ASX:ATX
36 GF Score
Price A$0.15
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics Buyback Yield %?

Amplia Therapeutics ASX:ATX 36 Buyback Yield % is -37.56 as of Jul. 03, 2026. GuruFocus rates ASX:ATX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 744 Biotechnology companies, Amplia Therapeutics ranks worse than 79.7% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Amplia Therapeutics's current buyback yield was -37.56%.

Amplia Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Buyback Yield % Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -53.68 -0.13 0.00 -58.74 -21.59

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -8.99 -58.74 -49.47 -21.59

ASX:ATX vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Amplia Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Buyback Yield % falls into.


ASX:ATX
36GF Score
Amplia Therapeutics Ltd ASX:ATX
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Amplia Therapeutics's Buyback Yield for the fiscal year that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-1.859 + 27.885) / 120.57192
=-21.59%

Amplia Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-1.859 + 27.885) / 120.57192
=-21.59%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -37.56 mean?
Amplia Therapeutics (ASX:ATX) has a Buyback Yield % of -37.56 as of Jul. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Amplia Therapeutics and its competitors. According to the industry distribution chart, Amplia Therapeutics ranks #593 out of 744 companies in the Biotechnology industry, placing it in the top 79.7%.
Is Amplia Therapeutics' Buyback Yield % too high?
Amplia Therapeutics' current Buyback Yield % is -37.56. Based on the distribution chart, Amplia Therapeutics ranks #593 out of 744 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Amplia Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Amplia Therapeutics ranks #593 out of 744 companies for Buyback Yield %. This places Amplia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Amplia Therapeutics and its competitors. Amplia Therapeutics's current Buyback Yield % is -37.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Buyback Yield % of -37.56. The current Buyback Yield % is -37.56. Amplia Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Buyback Yield % is -37.56 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
36GF Score

Get the complete analysis for ASX:ATX

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price